The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Gene therapy clinical trials worldwide to 2017: An update
Abstract
To date, almost 2600 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. Our database brings together global information on gene therapy clinical activity from trial databases, official agency sources, published literature, conference presentations and posters kindly provided to us by individual investigators or trial sponsors. This review presents our analysis of clinical trials that, to the best of our knowledge, have been or are being performed worldwide. As of our November 2017 update, we have entries on 2597 trials undertaken in 38 countries. We have analysed the geographical distribution of trials, the disease indications (or other reasons) for trials, the proportions to which different vector types are used, and the genes that have been transferred. Details of the analyses presented, and our searchable database are available via The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide website at: http://www.wiley.co.uk/genmed/clinical. We also provide an overview of the progress being made in gene therapy clinical trials around the world, and discuss key trends since the previous review, namely the use of chimeric antigen receptor T cells for the treatment of cancer and advancements in genome editing technologies, which have the potential to transform the field moving forward.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“About 18.5% of clinical trials use this vector for gene therapy [57].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [57]
In the citing paper
“Furthermore, some viral vectors (eg, Adenovirus vector, Herpesviral vector) are toxic and can be immunogenic.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [22]
In the citing paper
“The AV vector now represents 1 of the 3 major viral vector categories in the gene therapy toolbox, along with AAV and lenti/retrovirus vector systems.”
From Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges (2020) · cites this paper as [22]
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Flagged first, then by citations
Research works printed but not linked: 6
- Aiuti A, 2009, Ten years of gene therapy for primary immune deficiencies. Hematology 2009 – the Education Program of the American Society of Hematology, Education Program, 2009, 682
- GeorgeLA RagniMV Samelson‐JonesBJ et al.Preliminary results from a phase 1/2 dose escalation trial of an investigational AAV‐mediated gene therapy for hemophilia A. American Society of Hematology 59th Annual Meeting and Exposition. Online Conference Proceedings; 9 December2017.https://ash.confex.com/ash/2017/webprogram/Paper108679.html[30 January 2018].
- Constable IJ, 2016, Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT‐1 for wet age‐related macular degeneration. E, Biol Med, 14, 168
- MonahanP WalshCE PowellJS et al.Update on a phase 1/2 open‐label trial of BAX335 an adeno‐associated virus 8 (AAV8) vector‐based gene therapy program for hemophilia B. Proceedings of the XXV International Society on Thrombosis and Haemostasis Conference.North Carolina USA:Carrboro;2015;13(Suppl 2): LB010):87.
- Abeona Therapeutics.Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO‐102 Gene Therapy For Patients with MPS IIIA: Clinical Trial Notification (CTN) Enables Initiation at 3rd Global Site and Accelerates Enrollment in the ABO‐102 MPS IIIA Gene Therapy Program. Abeona Therapeutics: Press Release 9 May2017.https://globenewswire.com/news-release/2017/05/09/980972/0/en/Abeona-Therapeutics-Receives-Regulatory-Approval-to-Initiate-Clinical-Trial-in-Australia-with-ABO-102-Gene-Therapy-For-Patients-with-MPS-IIIA.html[3 April 2018].
- Amgen.FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US. AMGEN website: Press Release 27 October2015.http://www.amgen.com/media/news‐releases/2015/10/fda‐approves‐imlygic‐talimogene‐laherparepvec‐as‐first‐oncolytic‐viral‐therapy‐in‐the‐us/[30 January 2018].
Cited by
Sorted by citations
Items 201–300 of 903
Cancer Treatment Evolution from Traditional Methods to Stem Cells and Gene Therapy
Dong, C., He, W., Li, Q., Lü, Y., Ju, D., Gu, Y., & Zhao, K. (2021) · Current Gene Therapy · doi:10.2174/1566523221666211119110755 · Cited by 40
Histidine‐enhanced gene delivery systems: The state of the art
Hooshmand, S. E., Sabet, M. J., Hasanzadeh, A., Mousavi, S. M. K., Moghaddam, N. H., Hooshmand, S. A., Rabiee, N., Liu, Y., Hamblin, M. R., & Karimi, M. (2022) · The Journal of Gene Medicine · doi:10.1002/jgm.3415 · Cited by 41
Yom-Tov, N., Guy, R., & Offen, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114535 · Cited by 42
Calixarene‐Embedded Nanoparticles for Interference‐Free Gene–Drug Combination Cancer Therapy
Liu, Q., Zhang, T., Zheng, Y., Wang, C., Kang, Z., Zhao, Y., Chai, J., Li, H., Guo, D., Liu, Y., et al. (2021) · Small · doi:10.1002/smll.202006223 · Cited by 39
Gharbavi, M., Johari, B., Rismani, E., Mousazadeh, N., Taromchi, A. H., & Sharafi, A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00699 · Cited by 38
Bacteriophage-Mediated Cancer Gene Therapy
Petrov, G., Dymova, M., & Richter, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214245 · Cited by 38
Adenovirus as a Vector and Oncolytic Virus
Matsunaga, W., & Gotoh, A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45060307 · Cited by 43
Translating current biomedical therapies for long duration, deep space missions
Iosim, S., MacKay, M. J., Westover, C. D., & Mason, C. E. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz022 · Cited by 39
Elkashif, A., Alhashimi, M., Sayedahmed, E. E., Sambhara, S. R., & Mittal, S. K. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1345 · Cited by 41
Recombinant adeno-associated virus 8 vector in gene therapy: Opportunities and challenges
Zhao, L., Yang, Z., Zheng, M., Shi, L., Gu, M., Liu, G., Miao, F., Chang, Y., Fanghua, H., & Tang, N. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.010 · Cited by 40
Zhang, W., Hou, Y., Yin, S., Miao, Q., Lee, K., Zhou, X., & Wang, Y. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02580-8 · Cited by 43
Nano-vectors for CRISPR/Cas9-mediated genome editing
Yang, P., Lee, A. Y.-T., Xue, J., Chou, S., Lee, C., Tseng, P., Zhang, T. X., Zhu, Y., Lee, J., Chiou, S., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101482 · Cited by 41
Munir, M., Kett, V. L., Dunne, N., & McCarthy, H. O. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03256-4 · Cited by 37
Delivery of genome editing tools: A promising strategy for HPV-related cervical malignancy therapy
Aghamiri, S., Talaei, S., Roshanzamiri, S., Zandsalimi, F., Fazeli, E., Aliyu, M., Avarvand, O. K., Ebrahimi, Z., Keshavarz‐Fathi, M., & Ghanbarian, H. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1747429 · Cited by 37
Genetically-modified Stem Cell in Regenerative Medicine and Cancer Therapy; A New Era
Verdi, J., Hassanzadeh, A., Shamlou, S., Yousefi, N., & Nikoo, M. (2021) · Current Gene Therapy · doi:10.2174/1566523221666210707125342 · Cited by 36
Brgles, M., Šantak, M., Halassy, B., Forčić, D., & Tomašić, J. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s27471 · Cited by 36
A Polymeric Nanoparticle Formulation for Targeted mRNA Delivery to Fibroblasts
Rodrigues, A. F., Rebelo, C., Simões, S. M. N., Paulo, C., Pinho, S. L. C., Francisco, V., & Ferreira, L. (2022) · Advanced Science · doi:10.1002/advs.202205475 · Cited by 33
Non-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery
Sahu, K. K., Pradhan, M., Singh, D., Singh, M. R., & Yadav, D. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104152 · Cited by 36
Corneal Regeneration Using Gene Therapy Approaches
Sarkar, S., Panikker, P., D’Souza, S., Shetty, R., Mohan, R. R., & Ghosh, A. (2023) · Cells · doi:10.3390/cells12091280 · Cited by 36
Ligand Decorated Chitosan as an Advanced Nanocarrier for Targeted Delivery: A Critical Review
Qindeel, M., Ahmed, N., Khan, G. M., & Rehman, A. U. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0490 · Cited by 35
Targovnik, A. M., Simonin, J. A., Callum, G. J. M., Smith, I., Warlet, F. U. C., Nugnes, M. V., Miranda, M. V., & Belaich, M. N. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11615-1 · Cited by 34
Treacy, O., Ryan, A. E., Heinzl, T., O’Flynn, L., Cregg, M., Wilk, M. M., Odoardi, F., Lohan, P., O’Brien, T., Nosov, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042662 · Cited by 35
Effect of YAP1 silencing on esophageal cancer
Zhao, S., Zhao, J., Li, X., Yang, Y., Zhu, D., Zhang, C., Liu, D., & Wu, K. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s102338 · Cited by 35
Peptide ligands for the affinity purification of adeno‐associated viruses from HEK 293 cell lysates
Chu, W., Shastry, S., Barbieri, E., Prodromou, R., Greback‐Clarke, P., Smith, W. K., Moore, B., Kilgore, R., Cummings, C., Pancorbo, J., et al. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28495 · Cited by 33
Stimuli-responsive nanomaterials for the precision delivery of mRNA cancer vaccines
Srivastava, R. (2025) · Nano Trends · doi:10.1016/j.nwnano.2025.100147 · Cited by 36
Zhang, L., & Wang, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112075 · Cited by 36
Activation of Innate Immunity by Therapeutic Nucleic Acids
Bishani, A., & Chernolovskaya, E. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413360 · Cited by 35
Curative Cell and Gene Therapy for Osteogenesis Imperfecta
Schindeler, A., Lee, L. R., O’Donohue, A. K., Ginn, S. L., & Munns, C. F. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4549 · Cited by 39
Self-citationPidre, M. L., Arrías, P. N., Morales, L. C. A., & Romanowski, V. (2022) · Viruses · doi:10.3390/v15010080 · Cited by 37
Pérez-Sánchez, J., Middleton, S. J., Pattison, L. A., Hilton, H., Awadelkareem, M. A., Zuberi, S. R., Renke, M. B., Hu, H., Yang, X., Clark, A. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh3839 · Cited by 35
Recent advances in aerosol gene delivery systems using non-viral vectors for lung cancer therapy
Lee, A. Y., Cho, M., & Kim, S. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1641083 · Cited by 34
Kawka, K., Wilton, A. N., Madadkar, P., Medina, M. F. C., Lichty, B. D., Ghosh, R., & Latulippe, D. R. (2020) · Separation and Purification Technology · doi:10.1016/j.seppur.2020.117503 · Cited by 33
Optimizing pDNA Lipo-polyplexes: A Balancing Act between Stability and Cargo Release
Berger, S., Levačić, A. K., Hörterer, E., Wilk, U., Benli‐Hoppe, T., Wang, Y., Öztürk, Ö., Luo, J., & Wagner, E. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.0c01779 · Cited by 33
Tuohy, G., & Megaw, R. D. (2021) · Biomolecules · doi:10.3390/biom11050760 · Cited by 33
Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights
Ersöz, E., & Demir‐Dora, D. (2024) · Drug Development Research · doi:10.1002/ddr.22187 · Cited by 34
Battling Neurodegenerative Diseases with Adeno-Associated Virus-Based Approaches
Mijanović, O., Branković, A., Borovjagin, A. V., Butnaru, D. V., Bezrukov, E. A., Sukhanov, R. B., Shpichka, A. I., Timashev, P. S., & Ulasov, I. V. (2020) · Viruses · doi:10.3390/v12040460 · Cited by 32
What’s new in IBD therapy: An “omics network” approach
Fiocchi, C., & Iliopoulos, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104886 · Cited by 34
NIR light‐triggered nanomaterials‐based prodrug activation towards cancer therapy
Zhang, F., Wu, Q., & Liu, H. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1643 · Cited by 32
Global Governance of Human Genome Editing: What Are the Rules?
Marchant, G. E. (2021) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-111320-091930 · Cited by 35
The DREADDful Hurdles and Opportunities of the Chronic Chemogenetic Toolbox
Claes, M., Groef, L. D., & Moons, L. (2022) · Cells · doi:10.3390/cells11071110 · Cited by 36
The vicissitudes of gene therapy
Evans, C. H. (2019) · Bone and Joint Research · doi:10.1302/2046-3758.810.bjr-2019-0265 · Cited by 32
He, S., Li, Z., Xie, L., Lin, R., Yan, B., Li, B., Luo, L., Xv, Y., Wen, H., Liang, Y., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03261-w · Cited by 33
The Memory-Modifying Potential of Optogenetics and the Need for Neuroethics
Adamczyk, A. K., & Zawadzki, P. (2020) · NanoEthics · doi:10.1007/s11569-020-00377-1 · Cited by 37
SINEUPs: a novel toolbox for RNA therapeutics
Espinoza, S., Bon, C., Valentini, P., Pierattini, B., Tettey‐Matey, A., Damiani, D., Pulcrano, S., Sanges, R., Persichetti, F., Takahashi, H., et al. (2021) · Essays in Biochemistry · doi:10.1042/ebc20200114 · Cited by 33
DNA nuclear targeting sequences for enhanced non-viral gene transfer: An in vitro and in vivo study
Guen, Y. T. L., Pichon, C., Guégan, P., Pluchon, K., Haute, T., Quemener, S., Ropars, J., Midoux, P., Gall, T. L., & Montier, T. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.03.012 · Cited by 30
Treatment of Melanoma by Nano-conjugate-Delivered Wee1 siRNA
Zhang, X., Cai, A., Gao, Y., Zhang, Y., Duan, X., & Men, K. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00316 · Cited by 30
Wang, L., Zhang, D., Li, J., Li, F., Wei, R., Jiang, G., Xu, H., Wang, X., Zhou, Y., & Xi, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113935 · Cited by 30
Smart Strategies for Precise Delivery of CRISPR/Cas9 in Genome Editing
Hasanzadeh, A., Noori, H., Jahandideh, A., Moghaddam, N. H., Mousavi, S. M. K., Nourizadeh, H., Saeedi, S., Karimi, M., & Hamblin, M. R. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01112 · Cited by 30
Pan, X., Sands, S. A., Yue, Y., Zhang, K., LeVine, S. M., & Duan, D. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.008 · Cited by 29
Anti-ageing gene therapy: Not so far away?
Vaiserman, A. M., FALCO, E. D., Koliada, A. K., Maslova, O., & Balistreri, C. R. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100977 · Cited by 33
Treating Bietti crystalline dystrophy in a high-fat diet-exacerbated murine model using gene therapy
Qu, B., Wu, S., Jiao, G., Zou, X., Li, Z., Guo, L., Sun, X., Huang, C., Sun, Z., Zhang, Y., et al. (2020) · Gene Therapy · doi:10.1038/s41434-020-0159-3 · Cited by 29
Georgi, F., Andriasyan, V., Witte, R., Murer, L., Hemmi, S., Yu, L. X., Grove, M., Meili, N., Kuttler, F., Yakimovich, A., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01002-20 · Cited by 29
Li, Y., He, Z., Sigen, A., Wang, X., Li, Z., Johnson, M., Foley, R., Lara‐Sáez, I., Lyu, J., & Wang, W. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c05010 · Cited by 31
Liu, L., Liu, Y., Xu, B., Liu, C., Jia, Y., Liu, T., Fang, C., Wang, W., Ren, J., He, Z., et al. (2018) · Theranostics · doi:10.7150/thno.21693 · Cited by 30
Tanaka, T., Hanaoka, H., & Sakurai, S. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.08.002 · Cited by 27
The Ocular Gene Delivery Landscape
Sahu, B., Chug, I., & Khanna, H. (2021) · Biomolecules · doi:10.3390/biom11081135 · Cited by 28
Namiot, E. D., Smirnovová, D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228148 · Cited by 32
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A., Zacharaiah, U. G., Srivastava, A., & Marepally, S. K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.015 · Cited by 33
Exosome-based therapeutics in bone regeneration: from fundamental biology to clinical translation
Tajafrooz, F., Ghofrani, S., Sadeghghomi, F., Chamas, A. E. H., Rahimi, N., Mirakhor, A., Hooshiar, M. H., & Raee, A. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04686-8 · Cited by 35
Maurya, S., Mary, B., & Jayandharan, G. R. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.164 · Cited by 27
The Protein Corona Does Not Influence Receptor-Mediated Targeting of Virus-like Particles
Suchanova, J. Z., Hejtmánková, A., Neburková, J., Cígler, P., Forstová, J., & Španielová, H. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00240 · Cited by 28
A comparison of AAV-vector production methods for gene therapy and preclinical assessment
Davidsson, M., Negrini, M., Hauser, S., Svanbergsson, A., Lockowandt, M., Tomasello, G., Manfredsson, F. P., & Heuer, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-78521-w · Cited by 30
Sieste, S., Mack, T. M., Lump, E., Hayn, M., Schütz, D., Röcker, A., Meier, C. A., Kaygisiz, K., Kirchhoff, F., Knowles, T. P. J., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202009382 · Cited by 27
Gene therapy: challenges in cell culture scale-up
Shupe, J., Zhang, A., Odenwelder, D. C., & Dobrowsky, T. M. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102721 · Cited by 28
Clinical holds for cell and gene therapy trials: Risks, impact, and lessons learned
Wills, C. A., Drago, D., & Pietrusko, R. G. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101125 · Cited by 28
Current Trends in Viral Gene Therapy for Human Orthopaedic Regenerative Medicine
Venkatesan, J. K., Rey‐Rico, A., & Cucchiarini, M. (2019) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-019-00179-x · Cited by 28
Corneal fibrosis: From in vitro models to current and upcoming drug and gene medicines
Cubillo, L. T., Gürdal, M., & Zeugolis, D. I. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115317 · Cited by 28
Haughan, J. E., Jiang, Z., Stefanovski, D., Moss, K. L., Ortved, K. F., & Robinson, M. A. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2785 · Cited by 28
BMP gene delivery for skeletal tissue regeneration
Bez, M., Pelled, G., & Gazit, D. (2020) · Bone · doi:10.1016/j.bone.2020.115449 · Cited by 27
Wang, J., Zhou, X., Wang, H., Xiao, Q., Ding, K., Dong, X., Xu, S., Shen, B., Sun, J., Zhou, Z., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120156 · Cited by 27
A primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 28
Clinical Applications and Immunological Aspects of Electroporation-Based Therapies
da Luz, J. C. D. S., Antunes, F., Clavijo-Salomon, M. A., Signori, E., Tessarollo, N. G., & Strauss, B. E. (2021) · Vaccines · doi:10.3390/vaccines9070727 · Cited by 28
Maruyama, M., Moeinzadeh, S., Guzman, R. A., Zhang, N., Storaci, H. W., Utsunomiya, T., Lui, E., Huang, E. E., Rhee, C., Gao, Q., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120972 · Cited by 27
Dendrimers as Non-Viral Vectors in Gene-Directed Enzyme Prodrug Therapy
Chiş, A. A., Dobrea, C. M., Rus, L. L., Frum, A., Morgovan, C., Butucă, A., Totan, M., Juncan, A. M., Gligor, F. G., & Arseniu, A. M. (2021) · Molecules · doi:10.3390/molecules26195976 · Cited by 32
Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery
Meyer, A. H., Feldsien, T. M., Mezler, M., Untucht, C., Venugopalan, R., & Lefebvre, D. R. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041100 · Cited by 27
A novel plier-like gemini cationic niosome for nucleic acid delivery
Pengnam, S., Patrojanasophon, P., Rojanarata, T., Ngawhirunpat, T., Yingyongnarongkul, B., Radchatawedchakoon, W., & Opanasopit, P. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.04.032 · Cited by 27
Clinical and Translational Landscape of Viral Gene Therapies
Yudaeva, A., Kostyusheva, A., Kachanov, A., Brezgin, S., Ponomareva, N., Parodi, A., Pokrovsky, V. S., Lukashev, A. N., Chulanov, V., & Kostyushev, D. S. (2024) · Cells · doi:10.3390/cells13221916 · Cited by 30
Keyvani, A. H., Mohammadnejad, P., Pazoki–Toroudi, H., Gilabert, I. P., Chu, T., Manshian, B. B., Soenen, S. J., & Sohrabi, B. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c15536 · Cited by 26
Bioresponsive polyplexes – chemically programmed for nucleic acid delivery
Hager, S., & Wagner, E. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1526922 · Cited by 26
Self-assembling Peptides in Current Nanomedicine: Versatile Nanomaterials for Drug Delivery
Peng, F., Zhang, W., & Qiu, F. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190712154021 · Cited by 26
Lipoplex-based therapeutics for effective oligonucleotide delivery: a compendious review
Singh, P. P., Vithalapuram, V., Metre, S., & Kodipyaka, R. (2019) · Journal of Liposome Research · doi:10.1080/08982104.2019.1652645 · Cited by 26
Lee, L. R., Peacock, L., Lisowski, L., Little, D. G., Munns, C. F., & Schindeler, A. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.010 · Cited by 28
Hou, X., Shou, C., He, M., Xu, J., Cheng, Y., Yuan, Z., Lan, M., Zhao, Y., Yang, Y. A., Chen, X., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.010 · Cited by 26
Hutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 27
Liposomal formulations for treating lysosomal storage disorders
Tomsen-Melero, J., Merlo‐Mas, J., Carreño, A., Sala, S., Córdoba, A., Veciana, J., González‐Mira, E., & Ventosa, N. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114531 · Cited by 26
Aghbash, P. S., Hemmat, N., Baradaran, B., & Baghi, H. B. (2023) · European journal of medical research · doi:10.1186/s40001-023-01014-9 · Cited by 26
Lu, Y., Jiang, W., Wu, X., Huang, S., Huang, Z., Shi, Y., Dai, Q., Chen, J., Ren, F., & Gao, S. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s180957 · Cited by 25
Review of the Biomolecular Modification of the Metal-Organ-Framework
Xing, Q., Pan, Y., Hu, Y., & Wang, L. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00642 · Cited by 26
Metabolite-Based Modification of Poly( l -lysine) for Improved Gene Delivery
Urello, M. A., Xiang, L., Colombo, R., Ma, A., Joseph, A., Boyd, J., Peterson, N. C., Gao, C., Wu, H., & Christie, R. J. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00614 · Cited by 25
Hosen, M. J., Anwar, S., Mourosi, J. T., Chakraborty, S., Miah, M. F., & Vanakker, O. M. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01804-6 · Cited by 25
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
Garrison, L. P., Pezalla, E., Towse, A., Yang, H., Faust, E., Wu, E. Q., Li, N., Sawyer, E. K., & Recht, M. (2021) · Value in Health · doi:10.1016/j.jval.2021.05.008 · Cited by 25
Transcriptomic analysis of the innate immune response to in vitro transfection of plasmid DNA
Warga, E., Anderson, J. L., Tucker, M., Harris, E., & Elmer, J. J. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.025 · Cited by 28
Adenovirus-Mediated ABCC6 Gene Therapy for Heritable Ectopic Mineralization Disorders
Huang, J., Snook, A. E., Uitto, J., & Li, Q. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.12.017 · Cited by 25
The Landscape of Early Clinical Gene Therapies outside of Oncology
Rittié, L., Athanasopoulos, T., Calero-Garcia, M., Davies, M. L., Dow, D. J., Howe, S. J., Morrison, A., Ricciardelli, I., Saudemont, A., Jespers, L. S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.002 · Cited by 25
Synthesis and biophysical evaluation of carbosilane dendrimers as therapeutic siRNA carriers
Zawadzki, S., Ortiz, Á. M., Okła, E., Kędzierska, M., García‐Gallego, S., Ortega, P., de la Mata, F. J., Michlewska, S., Makowski, T., Йонов, М., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51238-w · Cited by 24
Naghib, S. M., Ahmadi, B., & Mozafari, M. R. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266293173240506054439 · Cited by 24
Colorectal cancer spectrum: From subtypes and epidemiology to oncotherapies
Agrawal, N., Lanjhiyana, S. K., Jaiswal, M., Siddiqui, M. A., & Gupta, S. (2025) · Gastroenterology & Endoscopy · doi:10.1016/j.gande.2025.01.002 · Cited by 26
Epidermal growth factor receptor targeted methotrexate and small interfering RNA co‐delivery
Steinborn, B., Truebenbach, I., Morys, S., Lächelt, U., Wagner, E., & Zhang, W. (2018) · The Journal of Gene Medicine · doi:10.1002/jgm.3041 · Cited by 24
Yang, O., Tao, Y., Qadan, M., & Ierapetritou, M. (2022) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-022-09645-x · Cited by 24
Pseudotyped lentiviral vectors: Ready for translation into targeted cancer gene therapy?
Deng, L., Liang, P., & Cui, H. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.03.007 · Cited by 27
Metadata
- Authors
- Ginn, S. L., Amaya, A. K., Alexander, I. E., Edelstein, M., & Abedi, M. R.
- Affiliations
- The University of Sydney (AU)
- Chatham House (GB)
- Uppsala University Hospital (SE)
- Corresponding author
- Ginn, Samantha L.
- Venue
- The Journal of Gene Medicine
- Publisher
- Wiley
- Published
- 2018-04-19
- Volume
- 20
- Issue
- 5
- Pages
- e3015-e3015
- ISSN
- 1099-498X (ISSN-L)
- 1521-2254
- OpenAlex
- W2983048398
- Cited by
- 903
- References
- 146
- Citations by year
- 2026: 31 · 2025: 68 · 2024: 86 · 2023: 77 · 2022: 124 · 2021: 141 · 2020: 151 · 2019: 148 · 2018: 36
- FWCI
- 16.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Gene Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- gene therapy, clinical trials, clinical trial database, gene therapy vectors, disease indications, chimeric antigen receptor T cells, cancer immunotherapy, genome editing, clinical trial trends
- MeSH terms
- Clinical Trials as Topic, Humans, Neoplasms, Global Health, Genetic Therapy, Immunotherapy, Adoptive, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review